论文部分内容阅读
GlaxoSmithKline公司的烷化剂美法仑片剂（melphalan,Alkeran）已在日本上市,其适应证为治疗恶性瘤（包括白血病、恶性淋癌、多发性骨髓瘤小儿实体肿瘤）中罕见的造血干细胞移植的预处理。
GlaxoSmithKline’s alkylating agent melphalan (Alkeran) has been marketed in Japan as indications for rare hematopoietic stem cell transplantation in the treatment of malignant tumors, including leukemia, malignant lymphoma, and multiple myeloma Pretreatment.